The Problem You Are Facing
Your mid-size pharma is running six AI vendors right now.
Let me guess what they are. A pharmacovigilance AI from one specialist vendor for case intake and signal detection. A separate GenAI tool from your CRM platform for sales rep coaching. A medical affairs AI from a third vendor for KOL research and competitive intelligence. An MLR review AI from a fourth vendor for promotional content. A content personalization tool from your shopper marketing partner. And a "co-pilot" from one of the hyperscalers your CIO signed last year because the procurement team got a discount.
Each one works. Each one was approved with a real business case. Each one has an internal champion. And each one is now on the AI vendor sprawl chart your CFO is starting to ask about.
You are not alone in this. The average large enterprise now runs over a hundred SaaS applications. In pharma specifically, the AI vendor landscape now exceeds one hundred and fifty named vendors. Across industries, fifty-two percent of software licenses go unused. The average company has four to seven orphaned apps and seven duplicate subscriptions. Sixty-eight percent of CIOs say they will consolidate vendor agreements in 2026.
The structural problem is bigger than the licensing cost. Six AI vendors means six governance regimes, six audit surfaces, six prompt engineering approaches, six compliance attestations, six data access paths, and six places a regulator could ask "show me the human oversight architecture for this system."
Mid-size pharma cannot run a coherent AI program out of that. You are running six pilots in trench coats.
And the EU AI Act, the FDA-EMA joint principles, and the FDA OPDP enforcement wave have already made it clear that the consolidation conversation is no longer optional. By 2027, every high-risk AI system in your portfolio needs a documented governance architecture. If you have six of them, you have six audits ahead of you. If you have one, you have one.
This is the consolidation pattern I deploy. Here is what it looks like.
Why It Keeps Happening
Three structural reasons for the sprawl.
First, the procurement model. Each AI vendor was sold into a different function: PV bought one, commercial bought another, medical bought a third, IT bought a fourth. The vendors compete to land inside their function silo. Nobody owns the cross-functional view of what your AI portfolio actually looks like until it is already fragmented.
Second, the speed-vs-architecture tradeoff. Buying a point solution for one function takes three months. Building an architecture across functions takes a year. Brand and function leaders consistently choose the three-month answer because their performance review is on a quarterly cycle. The architecture conversation gets deferred until the sprawl forces it.
Third, the absence of a unified buyer. Most mid-size pharma does not have a Chief AI Officer or a documented AI operating model. Each function buys what it needs, when it needs it, from the vendor that runs the best demo that month. The sprawl is the inevitable output of that purchasing pattern.
The result is six AI vendors, six contracts, six implementation teams, and six different opinions on what your AI strategy is.
The Solution
I deploy a sixteen-week consolidation pattern that takes your mid-size pharma from six AI vendors to one unified agent layer, built on the Human in the Loop architecture.
The architecture is the same one I have written about before: six layers, governance as the spine, designed around the regulatory boundary the EU AI Act and the FDA-EMA principles have drawn. Identity calibration, data access, routing and cascade, preparation, human oversight, learning. One agent layer that absorbs the workloads currently distributed across your six vendors.
The consolidation pattern itself has four phases.
Weeks 1-3: AI portfolio audit.
We map every AI vendor in your environment against three criteria. What workload they actually carry today. What governance regime they operate under. What contractual exit looks like. The output is a complete portfolio inventory with three categories: absorb into the agent layer, keep but integrate, sunset entirely. Most mid-size pharma discovers that three to four of the six vendors can be absorbed cleanly, one needs to stay as a specialist (typically the regulated PV or MLR platform), and one or two can be sunset immediately because they were never operational at scale.
Weeks 4-8: Foundation build.
The unified agent layer is stood up. Identity calibration and data access layers are configured against your CRM, your clinical trial systems, your prescribing data, your MLR libraries, your pharmacovigilance archives. Governance spine is documented. Routing logic is encoded for the decision classes the absorbed vendors used to handle.
Weeks 9-12: Migration of the first absorbed workloads.
Two to three workloads from the existing vendors are migrated into the agent layer. Typical first migrations: sales rep coaching, MLR pre-screening, KOL research and briefing, cross-functional decision routing. Each migration includes parallel run, baseline-to-pilot performance comparison, and a documented sunset plan for the legacy vendor contract.
Weeks 13-16: Vendor sunset and platform extension.
The legacy vendors marked for sunset are contractually exited. The agent layer is extended to additional workloads. The governance framework is finalized for inspection-readiness. By week sixteen, your AI portfolio looks fundamentally different.
What the End State Looks Like
After the sixteen-week consolidation, the picture changes structurally.
Where you had six vendor contracts, you now have one agent platform and (typically) one retained specialist vendor for the regulated PV or MLR workload that genuinely justifies its own platform.
Where you had six governance regimes, you now have one documented operating model that maps cleanly to the EU AI Act risk tiers, the FDA-EMA joint principles, and your internal SOPs.
Where you had six implementation teams and six prompt engineering approaches, you now have one team operating the agent layer across functions with a shared playbook.
Where you had a fragmented audit surface that no single person could explain end-to-end, you now have a unified audit trail that the compliance function can walk an inspector through in under an hour.
And where you had six P&L line items competing for next year's AI budget, you now have a consolidated AI spend line that the CFO can model against actual business outcomes.
Why This Will Work for Your Organization
Three reasons.
First, the consolidation savings are real. Industry data on vendor consolidation shows IT cost reductions of twenty to forty percent when six-vendor sprawl is collapsed into a unified platform. Even at the conservative end, that is multi-million-dollar annual savings for a mid-size pharma running an active AI portfolio.
Second, the regulatory clock is compressing the window. EU AI Act high-risk obligations are already in effect for standalone systems. MDR/IVDR-embedded AI follows in August 2027. The companies that consolidate before those deadlines are inspecting one architecture. The companies that wait are inspecting six.
Third, every subsequent AI deployment becomes structurally cheaper. Once the agent layer is operational, adding a new use case is a configuration change, not a vendor procurement cycle. Your AI roadmap velocity changes from "one major deployment per year" to "one extension every quarter."
What You Get
The consolidation engagement delivers four things.
A written AI portfolio audit showing every vendor, every workload, every governance regime, every contract, and the recommended absorb/integrate/sunset disposition per vendor. A live unified agent layer deployed across two to three priority workloads by week twelve. A documented vendor sunset plan with renegotiation playbooks for the contracts being exited. A board-ready AI operating model summary showing the new architecture, the consolidation savings, and the extension roadmap.
How to Start
The next step is a thirty-minute AI portfolio call.
You walk me through your current AI vendor landscape: which vendors, which functions, which contracts, which workloads. I walk you through which of those vendors are absorption candidates, which are retained specialists, which are sunset targets, and what a sixteen-week consolidation engagement would look like for your specific portfolio.
The output of the call is a one-page consolidation assessment specific to your pharma. No procurement process required for the call. No vendor evaluation. No NDA on the way in.
If you have more than three active AI vendors and no unified governance architecture across them, this is the call.
Book a 30-minute AI portfolio call →
The mid-size pharma companies that consolidate in the next twelve months will run their AI portfolio at a structurally lower cost, with a coherent governance architecture, and with the velocity to deploy new use cases in quarters instead of years. The ones that do not will keep paying six invoices, defending six audit surfaces, and watching their AI budget compound without compounding their business outcomes.
